Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.
Hepatocellular carcinoma (HCC) is the most common form of liver cancer. It is the seventh most common type of cancer worldwide and the second most common cause of cancer death worldwide. Most risk factors associated with the development of HCC lead initially to liver cirrhosis, which can be found in the majority of HCC patients and remains the underlying disease in these patients. Using primary research conducted with expert , European, and Japanese HCC specialists, including gastroenterologists, hepatologists, and medical oncologists, this report provides a comprehensive analysis of the competitive landscape and market opportunity for HCC. It includes a comprehensive analysis of patient populations, current therapies and medical practices, unmet needs, and emerging therapies. HCC is potentially curable only when detected in its early stages and can be treated by tumor resection, tumor ablation, or liver transplantation. Current treatment options for advanced HCC are very limited, and only one targeted therapy, sorafenib (Bayer/Onyx’s Nexavar), is approved for treatment in this setting.
Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, and Japan.
Primary research: 10 country-specific interviews with thought leaders (gastroenterologists, hepatologists, and medical oncologists).
Epidemiology: Diagnosed incident cases of HCC by stage of disease. Clinical- and market-relevant drug-treatable populations.
Emerging therapies: Phase II: 12; Phase III/PR: 9.